P-18: Decreased Expression of Suz12 Gene in CML Patients (Pages: 47-47)

Ghalandary M *, Hassania B , Akbari M , Behmanesh M ,


Objective: One of the most mechanism in developing of cancer is epigenetic changes which includes promoter DNA hypermethylation of tumor suppressor genes and the post-translational modifications that occur on histones. A variety of proteins are identified to play an important role in the regulation of this epigenetic changes. For example, Polycomb group proteins (PcG) have emerged as on of those chromatin regulatory factors. PcG proteins were first identified as regulator of homeotic genes in drosophila melangaster. During every cell cycle transition, these proteins maintain cell identity through regulation of chromatin structure. Suz12 is a component of Polycomb group proteins which its overexpression has been reported to be associated with many cancers. Moreover, its loss of expression leads to the amplified activity of progenitor and hematopoietic stem cells (HSC). For the reason that Chronic myeloid leukaemia originates from HSC as a consequent of t (9, 22) translocation the purpose of this study was to examine the expression of suz12 in CML patients in comparison with normal people. Materials and Methods: RNA extracted from14 patients and 15 normal peoples, reverse transcribed and amplified by RT-PCR technique. Results: Our study shows that the expression levels of suz12 in patients are lower than normal peoples. Conclusion: These finding are compatible with the fact that loss of SUZ12 function enhances hematopoietic stem cell activity and the role of epigenetic mechanism in developing cancer